We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current CATB market cap is 309.97M. The company's latest EPS is USD -2.0082 and P/E is -4.25.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -20.24M | -34.2M | -24.15M | -28.8M | -29.01M |
| Net Income | -17.73M | -31.41M | -19.93M | -24.17M | -24.53M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -27.09M | -37.44M | -194.98M | -53.5M | -83.03M |
| Net Income | -26.29M | -37.3M | -194.91M | -51.83M | -72.89M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 193.86M | 254.67M | 378.81M | 367.99M | 361.64M |
| Total Liabilities | 9.38M | 11.55M | 11.07M | 20.91M | 19.99M |
| Total Equity | 184.48M | 243.12M | 367.74M | 347.08M | 341.65M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 41.78M | 47.46M | 127.51M | 230.63M | 254.67M |
| Total Liabilities | 6.06M | 6.79M | 5.2M | 9.42M | 11.55M |
| Total Equity | 35.72M | 40.67M | 122.31M | 221.22M | 243.12M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -38.21M | -68.45M | -19.09M | -35.89M | -63.85M |
| Investing | 137.07M | 135.05M | -126.23M | -194.33M | -188.15M |
| Financing | 420k | 88.4M | 141.81M | 141.9M | 157.2M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -26.57M | -32.49M | -30.15M | -43.53M | -68.45M |
| Investing | -4.08M | 6.3M | -12.56M | -167.13M | 135.05M |
| Financing | 25.62M | 40.86M | 104.28M | 144.72M | 88.4M |
| Market Cap | 309.97M |
| Price to Earnings Ratio | -4.25 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 1.77 |
| Price to Book Ratio | 1.27 |
| Dividend Yield | - |
| Shares Outstanding | 36.3M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0.18 (2.09%) |
| Company Name | Catabasis Pharmaceuticals Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.astriatx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
